Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1986 1
1987 2
1988 3
1989 5
1990 2
1991 2
1992 5
1993 4
1994 3
1995 5
1996 5
1997 7
1998 3
1999 6
2000 3
2001 2
2002 5
2003 7
2004 10
2005 5
2006 7
2007 6
2008 8
2009 13
2010 13
2011 11
2012 10
2013 11
2014 8
2015 20
2016 19
2017 23
2018 22
2019 23
2020 27
2021 23
2022 18
2023 28
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

344 results

Results by year

Filters applied: . Clear all
Page 1
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.
Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, Böhringer S, Cambon-Thomsen A, Cecchin E, Cheung KC, Deneer VH, Dupui M, Ingelman-Sundberg M, Jonsson S, Joefield-Roka C, Just KS, Karlsson MO, Konta L, Koopmann R, Kriek M, Lehr T, Mitropoulou C, Rial-Sebbag E, Rollinson V, Roncato R, Samwald M, Schaeffeler E, Skokou M, Schwab M, Steinberger D, Stingl JC, Tremmel R, Turner RM, van Rhenen MH, Dávila Fajardo CL, Dolžan V, Patrinos GP, Pirmohamed M, Sunder-Plassmann G, Toffoli G, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium. Swen JJ, et al. Among authors: toffoli g. Lancet. 2023 Feb 4;401(10374):347-356. doi: 10.1016/S0140-6736(22)01841-4. Lancet. 2023. PMID: 36739136 Clinical Trial.
Idarubicin.
Crivellari D, Toffoli G, Lombardi D, Berretta M, Sorio R, Magri MD, Spazzapan S, Scuderi C, Veronesi A. Crivellari D, et al. Among authors: toffoli g. Tumori. 2002 Jan-Feb;88(1 Suppl 1):S73-4. doi: 10.1177/030089160208800122. Tumori. 2002. PMID: 11989932 No abstract available.
Biosensing Technologies for Therapeutic Drug Monitoring.
Meneghello A, Tartaggia S, Alvau MD, Polo F, Toffoli G. Meneghello A, et al. Among authors: toffoli g. Curr Med Chem. 2018;25(34):4354-4377. doi: 10.2174/0929867324666170720101736. Curr Med Chem. 2018. PMID: 28724346 Review.
Pharmacogenetics of irinotecan.
Toffoli G, Cecchin E, Corona G, Boiocchi M. Toffoli G, et al. Curr Med Chem Anticancer Agents. 2003 May;3(3):225-37. doi: 10.2174/1568011033482477. Curr Med Chem Anticancer Agents. 2003. PMID: 12769780 Review.
DNA Nanotechnology for Cancer Therapy.
Kumar V, Palazzolo S, Bayda S, Corona G, Toffoli G, Rizzolio F. Kumar V, et al. Among authors: toffoli g. Theranostics. 2016 Mar 20;6(5):710-25. doi: 10.7150/thno.14203. eCollection 2016. Theranostics. 2016. PMID: 27022418 Free PMC article. Review.
Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy.
Vianello C, Cocetta V, Catanzaro D, Dorn GW 2nd, De Milito A, Rizzolio F, Canzonieri V, Cecchin E, Roncato R, Toffoli G, Quagliariello V, Di Mauro A, Losito S, Maurea N, Scaffa C, Sales G, Scorrano L, Giacomello M, Montopoli M. Vianello C, et al. Among authors: toffoli g. Cell Death Dis. 2022 Apr 22;13(4):398. doi: 10.1038/s41419-022-04741-9. Cell Death Dis. 2022. PMID: 35459212 Free PMC article.
Novel immunotherapeutic approaches for hepatocellular carcinoma treatment.
Busato D, Mossenta M, Baboci L, Di Cintio F, Toffoli G, Dal Bo M. Busato D, et al. Among authors: toffoli g. Expert Rev Clin Pharmacol. 2019 May;12(5):453-470. doi: 10.1080/17512433.2019.1598859. Epub 2019 Apr 14. Expert Rev Clin Pharmacol. 2019. PMID: 30907177 Review.
344 results